拉贝洛尔辅助治疗早发型重度子痫前期患者的效果分析

Analysis of the Efficacy of Labetalol in Treatment of Patients with Early Onset Severe Preeclampsia

目的:探究拉贝洛尔辅助治疗早发型重度子痫前期(EOSP)患者的效果。方法:选取2016年1月-2018年6月在本院诊断及治疗的EOSP患者100例,采用随机数表法分为观察组及对照组,各50例。两组一般治疗相同,并使用硫酸镁治疗,观察组在此基础上给予拉贝洛尔。对比两组治疗前后收缩压、舒张压、心率、心脏指数及外周阻力,比较两组分娩方式及新生儿Apgar评分、不良反应。结果:治疗后,两组收缩压、舒张压及心率均低于治疗前,且观察组均低于对照组,差异均有统计学意义(P<0.05);治疗后,两组心脏指数均高于治疗前,外周阻力均低于治疗前,且观察组均优于对照组,差异均有统计学意义(P<0.05);两组分娩方式比较,差异无统计学意义(P>0.05),观察组Apgar评分≥8分的新生儿明显多于观察组(P<0.05);观察组不良反应总发生率为6.00%,低于对照组的26.00%(字2=7.440,P=0.006)。结论:拉贝洛尔辅助治疗EOSP效果显著,可有效控制血压,提高心脏功能,并改善新生儿缺氧状态。

Objective:To explore the efficacy of Labetalol in treatment of patients with early onset severe preeclampsia(EOSP).Method:A total of 100 EOSP patients diagnosed and treated in our hospital from January 2016 to June 2018 were selected.According to the random number table method,they were divided into observation group and control group,50 cases in each group.The two groups had the same general treatment,and Magnesium sulfate was used for treatment,the observation group was given Labetalol on this basis.The systolic blood pressure, diastolic blood pressure,heart rate,cardiac index and peripheral resistance between two groups before and after treatment were compared.The delivery mode,Apgar score and adverse reactions between two groups were compared.Result:After treatment,the systolic blood pressure,diastolic blood pressure and heart rate of two groups were lower than those of before treatment,and observation group were lower than those of control group,the differences were statistically significant(P<0.05).After treatment,the cardiac index of two groups were higher than those of before treatment,the peripheral resistance were lower than those of before treatment,and observation group were better than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in delivery mode between two groups(P>0.05).The Apgar score≥8 in observation group was significantly higher than that of observation group(P<0.05).The total incidence of adverse reactions in observation group was 6.00%,which was lower than 26.00% of control group(X^2=7.440,P=0.006).Conclusion:Labetalol is an effective adjuvant therapy for EOSP,which can effectively control blood pressure,improve cardiac function and improve neonatal hypoxia.